Maintaining more frequent GH release throughout the day rather than creating a single massive pulse. Another GHRH option is sermorelin, which has a shorter half-life (approximately 8–11 minutes) and requires precise timing. CJC-1295 NO DAC has a half-life of approximately 30 minutes, which aligns almost perfectly with ipamorelin's half-life of roughly 2 hours, allowing both peptides to reach peak plasma concentrations within the same 60–90 minute window. CJC-1295 NO DAC (modified GRF 1-29) is the gold standard GHRH analog for stacking with ipamorelin. Effective ipamorelin stacking follows three mechanistic pathways, each optimized for different research goals. It's rooted in receptor biology and verified across multiple clinical trials. Ipamorelin combined with a GHRH analog produces peak GH concentrations 300–500% higher than monotherapy, with no increase in adverse signals. Interestingly, a decrease in mean systolic blood pressure was observed as an effect of sermorelin treatment. However, as with the Corpas et al. study, no significant changes in testosterone levels were observed. This suggests that the timing and frequency of sermorelin treatment significantly affects IGF-1 levels, with a higher frequency of administration resulting in more significant IGF-1 increases. Essentially, sermorelin was found to augment the duration of rhythmic GH release without pushing serum levels above physiologic norms. Sermorelin therapy almost doubled the 12-h mean amount of GH released, but no significant changes to mean peak amplitude and number of peaks were observed. The older men had lower baseline IGF-1 levels when compared to the younger men but sermorelin treatment resulted in elevations in IGF-1 in a dose-response fashion to levels approaching those of the younger men. Measured outcomes included serum GH, IGF-1, IGFBP-3, and testosterone levels in addition to body weight, BMI, and waist-hip ratio. Ipamorelin binds exclusively to GHS-R1a receptors, which means it activates only one of several pathways capable of triggering GH release. Ipamorelin is a selective ghrelin receptor agonist designed to stimulate GH release without activating cortisol or prolactin pathways, which makes it exceptionally clean but limits its standalone amplitude. Click here to learn more about sermorelin therapy for women in Anaheim. Learn more about sermorelin therapy for men in Anaheim. However, few studies examining clinically significant endpoints such as body composition, exercise tolerance, and quality of life are currently available, limiting the ability to evaluate the clinical utility of GHS’s. Sermorelin and tesamorelin mimic GHRH and act as GHRH-R agonists, acting synergistically with ibutamoren. Private entities have marketed ibutamoren and GHRPs as supplements, and the drugs are also available through internet sites that focus on supplementation. Through chemical modification to increase potency, L-692,429 was created as a small molecule peptidomimetic agonist for GHRP-6 receptors. Subsequent work found that GHRPs act on both the pituitary and the hypothalamus, and that these peptides stimulate the release of GH without affecting the normal negative feedback mechanisms in the GH pathway that include somatostatin and IGF-1(24) (27). Subsequent work showed that GHRPs did not attenuate GHRH action when used prior to GHRH injection, but that GHRH and GHRP, when used together, synergistically stimulated GH release(24, 27). Based on the literature, current indications for the use of GHS’s include treatment of wasting and as treatment for GH deficiency. Elevations in IGF-1 levels in patients on GHS’s lead to increased insulin insensitivity, which can result in blood glucose elevations. In this trial, increased FFM did not result in increased strength, and abdominal visceral fat content was not affected(58). This trial did not show changes in visceral or abdominal fat mass when these parameters were examined(56). These studies, however, are limited by one-time administration of drug and a lack of somatic endpoints that assess changes in body composition over time. These results demonstrate that obesity blunts but does not eliminate the effect of GHRP on GH secretion, and that the synergistic effect of combination therapy with GHRH may be useful in restoring the GH axis in obese individuals. However, in a follow-up study, the responses of 12 obese and 8 non-obese subjects to a combination of GHRH and GHRP-6 (100mcg each, intravenously), were compared, with a lower GH response observed in obese than in non-obese patients(53). They tell somatotroph cells to produce more GH and prepare it in secretory granules for release. They bind to the GHRH receptor on somatotroph cells. Growth hormone is a 191-amino acid peptide hormone produced by somatotroph cells in the anterior pituitary gland. GH secretagogues work with the body’s endocrine system. Note that while ulimorelin is a ghrelin receptor agonist, it is not a GHS as it is peripherally selective and has little or no effect on GH secretion.Likewise, Adenosine is capable of eliciting hunger response as a ghrelin agonist but has little to no effect on GH secretion. Stacking two peptides that act on the same receptor, like ipamorelin and GHRP-2, produces additive effects at best and receptor competition at worst. Specifically, pairing a ghrelin receptor agonist (ipamorelin) with a GHRH receptor agonist (CJC-1295 or sermorelin). The idea that you can combine random growth hormone peptides and expect synergy is marketing, not science. If you’re on TRT, you’ve already taken a significant step toward better bone health. The direct research on CJC-1295 and bone mineral density in healthy adults is still emerging, but the indirect evidence is strong. Growth hormone and IGF-1 are the project managers who make sure the builders show up and do their job. The osteoclasts are the demolition team, breaking down old bone. The non-DAC version produces a cleaner pulse that more closely mimics the body’s natural rhythm. This decline is one of the reasons bone density starts to drop. Osteoblasts—the cells that build new bone—respond directly to GH and IGF-1 signaling.
